Medindia
Medindia LOGIN REGISTER
Advertisement

PCMA Statement on New Class-Action Lawsuit Against Drug Companies

Tuesday, January 31, 2017 Drug News
Advertisement
WASHINGTON, Jan. 30, 2017 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) issued the following statement on today's new class-action lawsuit against three makers of insulin drug products:
Advertisement

"While we're still reviewing the details of the lawsuit – in which pharmacy benefit managers (PBMs) are not named as defendants – it inexplicably attacks prescription drug rebates, long used to reduce costs in public programs like Medicaid and in the commercial market. 
Advertisement

While none of America's largest, most sophisticated health purchasers – including Fortune 500 companies, health plans, and Medicare Part D plans – are required to use the services of a PBM, almost all choose to because they reduce costs and improve the quality of benefits."

PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pcma-statement-on-new-class-action-lawsuit-against-drug-companies-300399022.html

SOURCE Pharmaceutical Care Management Association

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close